Clinical Trial Update: Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a coated didanosine (ddI EC)–containing HIV treatment regimen versus a typical anti-HIV regimen; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Didanosine EC (didanosine (enteric-coated))

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 3 | Status: COMPLETED